Updated:
Cyclerion Therapeutics
Peter Hecht's Cyclerion Therapeutics is a publicly traded CNS biotech spun from Ironwood Pharma in 2019 to develop sGC stimulators.
Cyclerion Therapeutics
Cyclerion Therapeutics launched in April 2019 as the pure-play R&D spinout of Ironwood Pharmaceuticals, a Cambridge-based gastrointestinal company that had discovered and commercialized the IBS-C drug linaclotide. Ironwood shareholders received Cyclerion shares in a tax-free distribution, creating an independent Nasdaq-listed entity (ticker: CYCN) led by Ironwood's founding CEO, Peter Hecht. The transaction split a $2 billion public company into two separate vehicles — one focused on commercial operations, the other on high-risk CNS and rare-disease drug development — a structure rarely seen outside academic spinouts. The firm's investment thesis centers entirely on modulating soluble guanylate cyclase, an enzyme pathway initially validated in cardiovascular and gastrointestinal indications. Cyclerion's clinical portfolio included praliciguat for diabetic nephropathy and heart failure with preserved ejection fraction, olinciguat for sickle cell disease, and multiple CNS-penetrant sGC stimulators targeting neuropsychiatric and neurodegenerative conditions. The company raised roughly $229 million in gross cash from Ironwood at spinout, supplemented by at-the-market equity offerings, and deployed capital across Phase 1–Phase 2 clinical trials in the United States. Strategic partnerships included a 2019 collaboration with the Dystonia Medical Research Foundation to study sGC modulation in movement disorders. Team size and current operational scale are not publicly disclosed in detail, though the firm consolidated operations to a single Cambridge headquarters and streamlined clinical programs after the Phase 2 praliciguat readout in 2019 failed to meet primary endpoints. In January 2024, Cyclerion announced a strategic pivot to focus on its CNS-penetrant sGC platform for neuropsychiatric disease, discontinuing all legacy vascular programs. The firm has maintained Nasdaq listing despite a sub-$10 million market capitalization as of early 2025, raising capital through controlled equity offerings rather than dilutive structured financings. Cyclerion's structural differentiator is its public-company format for early-stage biotech risk, granting individual investors venture-stage access to drug development normally reserved for specialized crossover funds and VCs. By operating as a listed C-corp with no parent conglomerate financing, the firm trades like an option on its CNS pipeline — a sink-or-swim architecture in which discipline on clinical execution determines survival rather than quarterly earnings pressure.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Peter Hecht
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Cyclerion?
Capital allocation decisions are made by the executive team led by CEO Peter Hecht, who co-founded Ironwood Pharmaceuticals and has overseen Cyclerion since its 2019 spinout. As a publicly traded development-stage company, material capital deployment decisions — including clinical trial initiation and partnership terms — are subject to board approval per SEC disclosure protocols.
What investment stages does Cyclerion typically target?
Cyclerion operates entirely at the preclinical-to-Phase 2 stage of drug development, taking molecules from discovery through early human proof-of-concept trials. The firm does not invest in commercial-stage assets and typically exits through out-licensing or sale to commercial-stage pharmaceutical companies once clinical validation is achieved.
How is Cyclerion related to Ironwood Pharmaceuticals?
Cyclerion was created via a tax-free spin-off from Ironwood Pharmaceuticals in April 2019, with Ironwood shareholders receiving one Cyclerion share for every Ironwood share held. The companies have operated as fully independent entities since the separation, with no ongoing financial or governance ties beyond shared historical leadership under Peter Hecht, who served as founding CEO of both firms.
Which sectors does Cyclerion explicitly avoid?
Cyclerion's 2024 strategic pivot explicitly ended investment in cardiovascular, renal, and metabolic disease programs, retiring praliciguat and olinciguat from active development. The firm now focuses solely on CNS-penetrant sGC stimulators for neuropsychiatric and neurodegenerative indications, avoiding non-neurological therapeutic areas entirely.
Is Cyclerion structured more like a family office or a venture firm?
Neither — Cyclerion is a publicly traded biotechnology corporation (Nasdaq: CYCN) with a single R&D focus, which makes it a self-financing drug-development entity that functions more like a publicly accessible venture-stage holding company. Unlike a VC fund, it has no limited partners and no set return timeline; unlike a single-family office, its capital comes from public equity investors rather than a private wealth pool.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: